Drugs / RVL-1201
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01848041 | May 2013 → Jan 2014 | ptosis | RVL Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02436759 | May 2015 → Nov 2016 | ptosis | RVL Pharmaceuticals, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-01-08 | RVL Pharmaceuticals, Inc. | Regulatory RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1% rvlpharma.com ↗
This milestone expands access in Japan to the first approved non-invasive treatment for blepharoptosis, where treatment options have primarily been limited to surgical procedures. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-01-08 | RVL Pharmaceuticals, Inc. | RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1% rvlpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RVL-1201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01848041 ↗ |
| Route | Topical | “RVL-1201 0.1% one full drop in each eye QD in the morning” NCT02436759 ↗ |